WntResearch is active in biotechnology and is developing a therapy to counteract cancer metastases. The company's research is focused on studies of the body's own protein WNT5A, which has been seen in studies to affect the ability of tumor cells to move and spread. The company's drug candidate Foxy-5 is a peptide that mimics the function of WNT5A and is being evaluated in the phase 2 clinical trial NeoFox, in patients with stage II-III colon cancer. The company was founded in 2007 and has its headquarters in Malmö.
CEO
Chairperson of the Board
Board
| Name | Capital % | Votes % | Date |
|---|---|---|---|
| Avanza Pension | 11,89 | 11,89 | 2023-06-28 |
| Nordnet Pensionsförsäkring | 6,31 | 6,31 | 2023-06-28 |
| Thomas Mellqvist | 2,14 | 2,14 | 2023-06-28 |
| Gunvald Berger | 2,01 | 2,01 | 2023-06-28 |
| Kjell Stenberg | 1,66 | 1,66 | 2023-06-28 |
| Lars-Erik Forsgårdh | 1,54 | 1,54 | 2023-06-28 |
| Niclas Evertsson | 1,51 | 1,51 | 2023-06-28 |
| Christian Haarlem | 1,18 | 1,18 | 2023-06-28 |
| Peter Nero | 1,10 | 1,10 | 2023-06-28 |
| Stefan Malmkvist | 1,02 | 1,02 | 2023-06-28 |
2023-11-16 Delårsrapport 2023-Q3